NDAINTRAVENOUSSOLUTION
Approved
Apr 2019
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
TRANEXAMIC ACID (tranexamic acid) by Molecular Devices is derivative, which diminishes the dissolution of hemostatic fibrin by plasmin. Approved for menorrhagia, postpartum hemorrhage, surgical blood loss. First approved in 2019.
Drug data last refreshed 21h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Tranexamic acid is an antifibrinolytic small molecule that prevents the breakdown of blood clots by inhibiting plasmin's binding to fibrin. It is indicated for menorrhagia, postpartum hemorrhage, and surgical blood loss via intravenous administration. The drug works by occupying lysine receptor binding sites on plasmin, thereby stabilizing the fibrin matrix and reducing excessive bleeding.
Peak
Product is in peak commercial phase with moderate competitive pressure (30), suggesting stable but not rapidly expanding team structure.
Mechanism of Action
derivative, which diminishes the dissolution of hemostatic fibrin by plasmin. In the presence of tranexamic acid, the lysine receptor binding sites of plasmin for fibrin are occupied, preventing binding to fibrin monomers, thus preserving and stabilizing fibrin's matrix structure. The…
Pharmacologic Class:
Antifibrinolytic Agent
Indications (3)
Worked on TRANEXAMIC ACID at Molecular Devices? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.